Our team at SOPHiA GENETICS has worked tirelessly over the past months to help advance the efforts of SARS-CoV-2 surveillance and research.
During the first stages of the pandemic, we leveraged our experience in NGS to develop and fine-tune a robust solution to conduct full-genome analysis of SARS-CoV-2. Genotyping of the virus has been instrumental to monitor viral evolution and its transmission, and to inform the efforts of those working to minimize the impact of the ongoing pandemic on the global health and economy.
However, the relentless speed at which efforts were undertaken by researchers around the world inevitably resulted in genotypes with variable quality. To improve these international viral monitoring efforts, our genomic experts at SOPHiA GENETICS have worked with international partners to offer new guidelines to optimize the quality and confidence in amplicon-based SARS-CoV-2 genotyping.
The broadly applicable and easy-to-implement guidelines we assembled should greatly contribute to increase the quality of reported SARS-CoV-2 genotypes. Overall, this will help ensure both the accuracy and reliability in the data that will lead to the future development of treatments and vaccines.
Dr. Zhenyu Xu, Chief Scientific Officer at SOPHiA GENETICS, leading these efforts expressed, “We hope that these recommendations will further support the ongoing efforts of the genomics community working to better understand and manage SARS-CoV-2.”